BridgeMD
StayDry
EU CTIS ID: 2023-510280-35-00
What this study is testing
The primary objective is to investigate if abrupt withdrawal versus phased withdrawal of pharmacotherapy (solifenacin and/or mirabegron) influences the risk of recurrence of incontinence.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- The participants custody holder(s) must voluntarily sign and date an informed consent prior to initiation any study specific procedures.
- Age 5 to 14 years (inclusive) at the time of signing the consent.
- Diagnose with urinary incontinence as per ICCS criteria.
- Pharmacological treatment with solifenacin and/or mirabegron.
- Continence has been achieved on pharmacological therapy with solifenacin and/or mirabegron.
- Previously withdrawal attempts are accepted.
You likely can't join if
- Neurogenic detrusor overactivity (neurogenic bladder)
See the full eligibility criteria
- The participants custody holder(s) must voluntarily sign and date an informed consent prior to initiation any study specific procedures.
- Age 5 to 14 years (inclusive) at the time of signing the consent.
- Diagnose with urinary incontinence as per ICCS criteria.
- Pharmacological treatment with solifenacin and/or mirabegron.
- Continence has been achieved on pharmacological therapy with solifenacin and/or mirabegron.
- Previously withdrawal attempts are accepted.
- Continence remained on the same dosage of medication for a minimum of three months.
- Neurogenic detrusor overactivity (neurogenic bladder)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.